{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:54:28Z","timestamp":1791222868193,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1019228"],"award-info":[{"award-number":["OPP1019228"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Infect Dis."],"published-print":{"date-parts":[[2016,3,15]]},"DOI":"10.1093\/infdis\/jiv528","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T20:39:33Z","timestamp":1447360773000},"page":"1013-1017","source":"Crossref","is-referenced-by-count":40,"title":["Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)"],"prefix":"10.1093","volume":"213","author":[{"given":"Kerri J.","family":"Penrose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi M.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Hamanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Else","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akil","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Mellors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,11,12]]},"reference":[{"key":"2016021908225250000_213.6.1013.1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00986-09"},{"key":"2016021908225250000_213.6.1013.2","doi-asserted-by":"publisher","DOI":"10.1310\/hct1403-81"},{"key":"2016021908225250000_213.6.1013.3","doi-asserted-by":"crossref","unstructured":"Ian McGowan AS , Duffill K , Shetler C et al . A phase 1 open label safety, acceptability, pharmacokinetic, and pharmacodynamic study of intramuscular TMC278 LA (the MWRI-01 Study). Presented at: HIV Research for Prevention Conference, Cape Town, South Africa, October 2014.","DOI":"10.1089\/aid.2014.5131a.abstract"},{"key":"2016021908225250000_213.6.1013.4","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283584500"},{"key":"2016021908225250000_213.6.1013.5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt463"},{"key":"2016021908225250000_213.6.1013.6","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt003"},{"key":"2016021908225250000_213.6.1013.7","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.1.18929"},{"key":"2016021908225250000_213.6.1013.8","doi-asserted-by":"crossref","unstructured":"Theys K , Camacho RJ , Gomes P , Vandamme AM , Rhee SY ; Portuguese HIV-1 Resistance Study Group. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. Clin Microbiol Infect 2015; 21:607.e1\u20138.","DOI":"10.1016\/j.cmi.2015.02.011"},{"key":"2016021908225250000_213.6.1013.9","first-page":"642","article-title":"2014 Update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top Antivir Med"},{"key":"2016021908225250000_213.6.1013.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04215-14"},{"key":"2016021908225250000_213.6.1013.11","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835cee6e"},{"key":"2016021908225250000_213.6.1013.12","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.118"},{"key":"2016021908225250000_213.6.1013.13","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.59"},{"key":"2016021908225250000_213.6.1013.14","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"2016021908225250000_213.6.1013.15","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.41.12.2781","article-title":"A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors","volume":"41","author":"Shi","year":"1997","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/213\/6\/1013\/17411273\/jiv528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T09:58:38Z","timestamp":1567331918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jiv528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,12]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,2,19]]},"published-print":{"date-parts":[[2016,3,15]]}},"alternative-id":["10.1093\/infdis\/jiv528"],"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiv528","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,12]]}}}